Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06795139 · ClinicalTrials.gov registry record · NA
Pilot of a Trial Enrollment Diversity Dashboard
A NA study of Leukemia and Acute Leukemia, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06795139: Active NA study of Leukemia and Acute Leukemia, sponsored by Dana-Farber Cancer Institute.
NCT06795139 is a NA study of Leukemia and Acute Leukemia that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 12 participants, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06795139, a NA study of Leukemia and Acute Leukemia, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to test the feasibility of a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) to ensure participant diversity in acute leukemia trial enrollment.
Primary Outcome
Utilization will be measured as the proportion of quarters where a participant accessed the dashboard divided by the total number of study quarters. Based on 12 participants over 4 three-month quarters, there are a total of 48 person-quarters available for analysis.
Conditions Studied
Interventions
- BEHAVIORAL Trial Enrollment Diversity Dashboard Behavioral
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-03-01 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What the registry record for NCT06795139 still lists
NCT06795139 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 487-participant average among 233 other Leukemia trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Trial Enrollment Diversity Dashboard Behavioral is the first listed.
NCT06795139 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06795139 about?
NCT06795139 is a clinical study titled "Pilot of a Trial Enrollment Diversity Dashboard". The goal of this study is to test the feasibility of a data visualization tool called the Trial Enrollment Diversity Dashboard (TEDD) to ensure participant diversity in acute leukemia trial enrollment.
What is the current status of trial NCT06795139?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2025-03-01. Estimated completion is 2027-06-30.
What conditions does trial NCT06795139 study?
This clinical trial studies the following conditions: Leukemia, Acute Leukemia.
What interventions are being tested in trial NCT06795139?
The interventions under investigation include: Trial Enrollment Diversity Dashboard Behavioral (BEHAVIORAL).
Who is sponsoring clinical trial NCT06795139?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06795139 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06795139's enrollment target sits among peer trials
12 212th of 233 higher than 21 of 233 other Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties
RECRUITING · NA
-
Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia
RECRUITING · NA
-
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
RECRUITING · NA
-
Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)
RECRUITING · NA
-
HEME Home Transfusion Program
RECRUITING · NA
-
Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress.
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI